Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
20. Dezember 2022 16:05 ET
|
Imago Biosciences, Inc.
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new...
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
12. Dezember 2022 11:30 ET
|
Imago Biosciences, Inc.
- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — -...
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
12. Dezember 2022 10:00 ET
|
Imago Biosciences, Inc.
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - -...
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
30. November 2022 16:05 ET
|
Imago Biosciences, Inc.
REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the...
Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
09. November 2022 16:05 ET
|
Imago Biosciences, Inc.
- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - -...
Imago BioSciences to Participate in Upcoming Investor Conferences
07. November 2022 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
03. November 2022 09:00 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
06. September 2022 16:05 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines...
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
12. August 2022 16:05 ET
|
Imago Biosciences, Inc.
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 - - Positive Data from the Ongoing...
Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
03. August 2022 16:57 ET
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines...